Quantitative Analysis of Nonhistone Lysine Methylation Sites and Lysine Demethylases in Breast Cancer Cell Lines
- PMID: 39778878
- PMCID: PMC11812601
- DOI: 10.1021/acs.jproteome.4c00685
Quantitative Analysis of Nonhistone Lysine Methylation Sites and Lysine Demethylases in Breast Cancer Cell Lines
Abstract
Growing evidence shows that lysine methylation is a widespread protein post-translational modification (PTM) that regulates protein function on histone and nonhistone proteins. Numerous studies have demonstrated that the dysregulation of lysine methylation mediators contributes to cancer growth and chemotherapeutic resistance. While changes in histone methylation are well-documented with extensive analytical techniques available, there is a lack of high-throughput methods to reproducibly quantify changes in the abundances of the mediators of lysine methylation and nonhistone lysine methylation (Kme) simultaneously across multiple samples. Recent studies by our group and others have demonstrated that antibody enrichment is not required to detect lysine methylation, prompting us to investigate the use of tandem mass tag (TMT) labeling for global Kme quantification without antibody enrichment in four different breast cancer cell lines (MCF-7, MDA-MB-231, HCC1806, and MCF10A). To improve the quantification of KDMs, we incorporated a lysine demethylase (KDM) isobaric trigger channel, which enabled 96% of all KDMs to be quantified while simultaneously quantifying 326 Kme sites. Overall, 142 differentially abundant Kme sites and eight differentially abundant KDMs were identified among the four cell lines, revealing cell line-specific patterning.
Keywords: TMT; lysine demethylases; lysine methylation.
Conflict of interest statement
The authors declare no competing financial interest.
Update of
-
Quantitative analysis of non-histone lysine methylation sites and lysine demethylases in breast cancer cell lines.bioRxiv [Preprint]. 2024 Sep 22:2024.09.18.613658. doi: 10.1101/2024.09.18.613658. bioRxiv. 2024. Update in: J Proteome Res. 2025 Feb 07;24(2):550-561. doi: 10.1021/acs.jproteome.4c00685. PMID: 39345446 Free PMC article. Updated. Preprint.
Similar articles
-
Quantitative analysis of non-histone lysine methylation sites and lysine demethylases in breast cancer cell lines.bioRxiv [Preprint]. 2024 Sep 22:2024.09.18.613658. doi: 10.1101/2024.09.18.613658. bioRxiv. 2024. Update in: J Proteome Res. 2025 Feb 07;24(2):550-561. doi: 10.1021/acs.jproteome.4c00685. PMID: 39345446 Free PMC article. Updated. Preprint.
-
LSD1 knockdown reveals novel histone lysine methylation in human breast cancer MCF-7 cells.Biomed Pharmacother. 2017 Aug;92:896-904. doi: 10.1016/j.biopha.2017.05.106. Epub 2017 Jun 7. Biomed Pharmacother. 2017. PMID: 28601046
-
Targeting histone demethylases as a potential cancer therapy (Review).Int J Oncol. 2022 Sep;61(3):103. doi: 10.3892/ijo.2022.5393. Epub 2022 Jul 8. Int J Oncol. 2022. PMID: 35801593 Review.
-
HDAC inhibitors induce global changes in histone lysine and arginine methylation and alter expression of lysine demethylases.J Proteomics. 2016 Feb 5;133:125-133. doi: 10.1016/j.jprot.2015.12.018. Epub 2015 Dec 22. J Proteomics. 2016. PMID: 26721445
-
The role and prospect of lysine-specific demethylases in cancer chemoresistance.Med Res Rev. 2023 Sep;43(5):1438-1469. doi: 10.1002/med.21955. Epub 2023 Apr 3. Med Res Rev. 2023. PMID: 37012609 Review.
References
-
- Liu S.; Hausmann S.; Carlson S. M.; Fuentes M. E.; Francis J. W.; Pillai R.; Lofgren S. M.; Hulea L.; Tandoc K.; Lu J.; Li A.; Nguyen N. D.; Caporicci M.; Kim M. P.; Maitra A.; Wang H.; Wistuba I. I.; Porco J. A.; Bassik M. C.; Elias J. E.; Song J.; Topisirovic I.; Rechem C. V.; Mazur P. K.; Gozani O. METTL13 Methylation of EEF1A Increases Translational Output to Promote Tumorigenesis. Cell 2019, 176 (3), 491–504. 10.1016/j.cell.2018.11.038. - DOI - PMC - PubMed
-
- Park S. H.; Fong K.; Kim J.; Wang F.; Lu X.; Lee Y.; Brea L. T.; Wadosky K.; Guo C.; Abdulkadir S. A.; Crispino J. D.; Fang D.; Ntziachristos P.; Liu X.; Li X.; Wan Y.; Goodrich D. W.; Zhao J. C.; Yu J. Posttranslational Regulation of FOXA1 by Polycomb and BUB3/USP7 Deubiquitin Complex in Prostate Cancer. Sci. Adv. 2021, 7 (15), eabe226110.1126/sciadv.abe2261. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous